Angiotensin II in Liver Transplantation

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

June 28, 2022

Primary Completion Date

September 1, 2025

Study Completion Date

September 1, 2026

Conditions
Liver Transplant; ComplicationsVasoplegia
Interventions
DRUG

Angiotensin II

Infusion of Angiotensin II initiated if participants require norepinephrine at a rate of \> 0.05 mcg/kg/min. The infusion will be titrated no more frequently than every 10 minutes during liver transplantation as a second line vasopressor and discontinued prior to leaving the operating room when the surgery is complete.

DRUG

Saline

Infusion of 0.9% saline initiated if participants require norepinephrine at a rate of \> 0.05 mcg/kg/min. The infusion will be titrated no more frequently than every 10 minutes during liver transplantation as a second line vasopressor and discontinued prior to leaving the operating room when the surgery is complete.

Trial Locations (1)

94143

RECRUITING

University of California, San Francisco, San Francisco

Sponsors
All Listed Sponsors
collaborator

La Jolla Pharmaceutical Company

INDUSTRY

lead

University of California, San Francisco

OTHER

NCT04901169 - Angiotensin II in Liver Transplantation | Biotech Hunter | Biotech Hunter